Member Info for dusterinmong

Lots happening here great time to hold for the real gains Il take the broker target of 95p with a dose of salts

But 50p this year is very possible and the added bonus of a poss buyout

Partnership once FDA is given also imho

17p this time last year without FDA and expanding European networks

Very cheap with what is ahead

Think that's poss but 1 bag minimum imho

Market catching on this far to cheap as this was over 25p a year ago without the FDA on the doorstep

Once aproval is given I can't see this company staying independent the valuation and money potential of the product will omjo attract a takeoutfrom a big pharma

Bargain at these levels with what is coming

Pretty much get a 2 bag on FDA approval imho back into the 20p area where is has been before.

Owl you really need to think about what your saying here more often

Atb

Should be a run to 10p this year then still only 20 odd mill market cap at 10p very cheap still

Fomo

Looks leaky RNS and it's a 2 bag minimum imho

Happy Easter all

Depends on discount if any ?

And it's still a way off from Is fine deciding at all imho

The RNS is a reality check

£173,000 (31 December 2022: £277,000).

On 1 February 2024, the Company issued 30,303,040 Ordinary Shares by way of subscription at a price of 1.65p per share, raising £0.5m before expenses. As previously announced, the Company will need to raise further funds in the coming weeks in order to strengthen its financial position and to meet its immediate working capital requirements; although there can be no guarantee of such, the directors remain confident that sufficient funding will be obtained as required. Accordingly, the financial statements have been prepared on a going concern basis, however there is material uncertainty due to the need for additional near-term funding. Please refer to the accounting policy note on going concern (Note 1 to the Financial Statements) for further information. 

£173,000 (31 December 2022: £277,000).

On 1 February 2024, the Company issued 30,303,040 Ordinary Shares by way of subscription at a price of 1.65p per share, raising £0.5m before expenses. As previously announced, the Company will need to raise further funds in the coming weeks in order to strengthen its financial position and to meet its immediate working capital requirements; although there can be no guarantee of such, the directors remain confident that sufficient funding will be obtained as required. Accordingly, the financial statements have been prepared on a going concern basis, however there is material uncertainty due to the need for additional near-term funding. Please refer to the accounting policy note on going concern (Note 1 to the Financial Statements) for further information. 

In the latest share talk with Zak Mir below he mentions this about getting more

Yes nice post either way holders should do well from here in

Just shows how some are under researched on value stocks.

Two other little gems I like are MTL debt free and URAH

the latter is just on verge of Emerald production and the former will be trading on a PE of one

Bonkers

Can't see it staying independent big pharma will want it imho

Yes a little Gem this one still under the radar of many should be over 10p now in a normal market

FDA opens up a lot of revenue

You allready had this issued in the RNS from the company this is just the same

Wake up